Trial reportClinical pharmacology in drug development2018
Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers.
Trial report in Clinical pharmacology in drug development, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Increased dopamine availability magnifies nicotine effects on cognitive control: A pilot study.Journal of psychopharmacology (Oxford, England) · 2020Trial
- Topical Delivery Systems for Plant-Derived Antimicrobial Agents: A Review of Current Advances.International journal of biomaterials · 2025Review
- Smoking reduction using electronic nicotine delivery systems in combination with nicotine skin patches.Psychopharmacology · 2023Article
- Development of Organs-on-Chips and Their Impact on Precision Medicine and Advanced System Simulation.Pharmaceutics · 2023Review
- Design and Preclinical Evaluation of Nicotine-Stearic Acid Conjugate-Loaded Solid Lipid Nanoparticles for Transdermal Delivery: A Technical Note.Pharmaceutics · 2023Article
- Development and Evaluation of a Human Skin Equivalent in a Semiautomatic Microfluidic Diffusion Chamber.Pharmaceutics · 2021Article
- Impact of Nicotine Replacement and Electronic Nicotine Delivery Systems on Fetal Brain Development.International journal of environmental research and public health · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Smoking continues to be a major preventable cause of early mortality worldwide, and nicotine replacement therapy has been demonstrated to increase rates of abstinence among smokers attempting to quit. Nicotine transdermal systems (also known as nicotine patches) attach to the skin via an adhesive layer composed of a mixture of different-molecular-weight polyisobutylenes (PIBs) in a specific ratio. This randomized, single-dose, 2-treatment, crossover pharmacokinetic (PK) trial assessed the bioequivalence of nicotine patches including a replacement PIB adhesive (test) compared with the PIB adhesive historically used on marketed patches (reference). The test and reference patches were bioequivalent, as determined by the PK parameters of C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.